“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts
Mumbai, India, June 11, 2021: Global pharma major Lupin Limited (Lupin) through its CSR arm, the Lupin Foundation, is donating five oxygen generation plants to assist the states of Maharashtra, Madhya Pradesh and Gujarat in their ongoing fight against the COVID-19 pandemic.
In preparation of ensuring India has a solid response for a potential third Covid wave, these five oxygen plants with a total capacity of 3840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra and Gujarat. The respective State governments will oversee the distribution of the oxygen produced at these plants to Government hospitals and COVID care centres. The company is in discussions with other states to assist them in their fight against the pandemic through similar initiatives.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/
For further information or queries please contact –
Head – Corporate Communications
General Manager – Corporate Communications